ITRACONAZOLE (ITRACONAZOLUM) - search results

Australia - English - Department of Health (Therapeutic Goods Administration)

sporanox itraconazole 100mg capsule blister pack

janssen-cilag pty ltd - itraconazole, quantity: 100 mg - capsule, hard - excipient ingredients: macrogol 20000; titanium dioxide; gelatin; hypromellose; indigo carmine; erythrosine; maize starch; sucrose - sporanox is indicated for use in adults for the treatment of: superficial dermatomycoses not responding to topical treatment. fungal keratitis which has failed to respond to topical treatment or where the disease is either progressing rapidly or is immediately sight threatening. pityriasis versicolor not responding to any other treatment. vulvovaginal candidiasis not responding to topical treatment. oral candidiasis in immunocompromised patients. onychomycosis caused by dermatophytes. systemic mycoses: -systemic aspergillosis, histoplasmosis, sporotrichosis. -treatment and maintenance therapy in aids patients with disseminated or chronic pulmonary histoplasmosis infection. -treatment of oropharyngeal and/or oesophageal candidiasis when fist line systemic antifungal therapy is inappropriate or has proven ineffective. -treatment of non-invasive candidiasis in non-neutropenic patients when first-line systemic antifungal therapy is inappropriate or has proven ineffective. this may be due to underlying pathology,

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

itraconazole 50mg/5ml oral solution sugar free

de pharmaceuticals - itraconazole - oral solution - 10mg/1ml

United States - English - NLM (National Library of Medicine)

itraconazole capsule, coated pellets

bryant ranch prepack - itraconazole (unii: 304nug5gf4) (itraconazole - unii:304nug5gf4) - itraconazole capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: 1. blastomycosis, pulmonary and extrapulmonary 2. histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and 3. aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin b therapy. specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology,serology) should be obtained before therapy to isolate and identify causative organisms. therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. itraconazole capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: 1. onychomycosis of the toenail, with or without fingernail involvemen

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

itraconazole

headway investments pty ltd - itraconazole - unknown - itraconazole active 0.0 - active constituent

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

itraconazole 100mg capsules

torrent pharma (uk) ltd - itraconazole - oral capsule - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

itraconazole 100mg capsules

medihealth (northern) ltd - itraconazole - oral capsule - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

itraconazole 50mg/5ml oral solution sugar free

medihealth (northern) ltd - itraconazole - oral solution - 10mg/1ml